Published: 6 June 2020
Author(s): Rosario Rossi, Francesca Coppi, Marisa Talarico, Giuseppe Boriani
Issue: July 2020
Section: Letter to the Editor

Since December 2019, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing global health emergency [1]. Elderly patients affected by chronic heart disease showed a high mortality risk in the setting of COVID-19 interstitial pneumonia [2,3]. This study aimed to assess if pharmacological cardio-active treatment reduce mortality risk in the setting of COVID-19 interstitial pneumonia.

Newsletters

Stay informed on our latest news!